Oruka Therapeutics (NASDAQ:ORKA) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Oruka Therapeutics (NASDAQ:ORKA) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, indicating a shift in analysts' perceptions of the stock's performance.
• Despite the downgrade, the consensus rating for ORKA remains "Buy" with an average price target of $40.38, as other analysts, like Wedbush and HC Wainwright, maintain positive outlooks on the stock.
• As of now, Oruka Therapeutics' stock opened at $15.37, having experienced a notable 12-month price range between a low of $5.49 and a high of $52.32.

Wall Street Zen downgraded shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) from a hold rating to a sell rating in a report issued on Saturday morning.

Several other brokerages have also issued reports on ORKA. Wedbush reissued an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 12th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Wednesday, July 23rd. Finally, BTIG Research started coverage on Oruka Therapeutics in a research report on Thursday, May 22nd. They issued a "buy" rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics presently has a consensus rating of "Buy" and an average target price of $40.38.

Oruka Therapeutics Trading Down 4.4%

Shares of Oruka Therapeutics stock traded down $0.6750 on Friday, hitting $14.5750. 74,359 shares of the company traded hands, compared to its average volume of 248,581. The stock's 50 day moving average price is $13.40 and its 200-day moving average price is $11.53. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $52.32. The company has a market cap of $545.85 million, a PE ratio of -5.19 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02. As a group, research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Fairmount Funds Management LLC raised its position in shares of Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares during the last quarter. VR Adviser LLC grew its stake in Oruka Therapeutics by 6.5% during the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock valued at $63,708,000 after acquiring an additional 200,000 shares in the last quarter. RTW Investments LP grew its stake in Oruka Therapeutics by 5.1% during the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock valued at $37,726,000 after acquiring an additional 95,001 shares in the last quarter. Braidwell LP grew its stake in shares of Oruka Therapeutics by 37.0% in the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company's stock valued at $16,133,000 after buying an additional 424,750 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Oruka Therapeutics by 374.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock valued at $25,730,000 after buying an additional 1,047,245 shares during the period. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.